FORMULATION AND EVALUATION OF DOCETAXEL TRIHYDRATE LOADED SELF-ASSEMBLED NANOCARRIERS FOR TREATMENT OF HER2 POSITIVE BREAST CANCER
Journal Title: Journal of Drug Delivery and Therapeutics - Year 2017, Vol 7, Issue 6
Abstract
Human Epidermal Growth Factor Receptor 2-positive (HER2-positive) breast cancer tend to be more aggressive among all breast cancers. Breast cancers with HER2 gene amplification or HER2 protein overexpression are called HER2-positive. It tends to grow faster and are more likely to spread and come back compared to HER2-negative breast cancers. HER2 positive breast cancer is often treated with chemotherapy drugs called anthracylines (e.g. doxorubicine, epirubicine), taxanes (e.g. Docetaxel, peclitaxel) as well as some others, usually in combination of two or more chemotherapy drugs1 but the development of potential drug delivery system by using nanotechnology is also the important aspect for the proper treatment of HER2 positive breast cancer. The aim of this study was to develop DTX-loaded self assembled nanocarriers (SANs) for treatment of HER2 positive breast cancer and also to evaluate their efficacy to release the drug by controlled manner. SANs were prepared from a glyceryl monooleate, Pluronic® F127 (0.5 – 1.5 % w/v) and Pluronic® F68 (0.25-1.0 %w/v) in different concentration with or without docetaxel trihydrate (DTX) (2.0%w/v) by high pressure homogenization, before preparation compatibility of drug and polymers was studied by differential scanning calorimetry (DSC) and FTIR spectroscopy. Prepared SANs was then subject to different evaluation test particle size, zeta potential, % entrapment efficiency, drug content, in vitro drug release study, measurement of pH, and stability study. Particle size of SANs prepared with Pluronic® F127 was found in the range of 170 nm to 280 nm whereas SANs with Pluronic® F68 was found between 200 to 240 nm and it shows more negative zeta potential value than -30 mV. More than 90 % of DTX was found to be entrapped in SANs formulations loaded with DTX 2.0% w/v. Drug released study revealed that formulation F9 containing 0.25% PF68 shows 89.59 % release after 12 h and F5 containing 1.0% PF127 releases 96.56% drug after 12 h. Results of one month stability study shows that the SANs formulations were found to be stable over a one month. Hence, the DTX-loaded SANs was act as an potential drug carrier to fulfill the demand of cancer therapeutics.
Authors and Affiliations
Nilesh Ramesh Rarokar
Keywords
Related Articles
- EP ID EP296367
- DOI 10.22270/jddt.v7i6.1530
- Views 81
- Downloads 0
An updated review on Anti-Alzheimer’s herbal drugs
Alzheimer’s disease (AD) is related to cognitive impairment, dementia observed generally in aged population due to neurodegeneration in an ongoing manner. It gradually worsens memory power of the patient. The hallmark di...
Formulation and evaluation of effervescent tablets: a review
Oral dosage forms are the most popular way of taking medication, despite having some disadvantages compared with other methods like risk of slow absorption of the medicament, which can be overcome by administering the dr...
DEVELOPMENT AND VALIDATION OF REVERSED PHASE HPLC METHOD FOR ESTIMATION OF CEFTRIAXONE IN PHARMACEUTICAL DOSAGE FORM
A simple, accurate rapid and precise RP-HPLC method has been developed and validated for determination of Ceftriaxone in bulk drug. The RP-HPLC separation was achieved on Promosil C-18, (250 mm, 4.6 mm, 5µm) using mobil...
ADVANCES IN SOLID DISPERSION TECHNOLOGY AND ITS APPLICATIONS IN THE DEVELOPMENT OF SOLID DOSAGE FORMS
Amorphous solid dispersions are extensively used as a strategy for improving the bioavailability of poorly water - soluble compounds in past decade. Therefore, the application of this technique proves to be an important...
COMPARATIVE EFFICACY OF GABAPENTIN A CONVENTIONAL ANTICONVULSANT WITH CONVENTIONAL ANALGESIC TREMADOL IN VISCERAL PAIN MODEL OF RODENTS
Carabmazepine is an established drug for trigeminal neuralgia while gabapentin has been tried in postoperative pain but its effectiveness in visceral pain and when compared to conventional analgesics needs to be evaluate...